{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:13:20Z","timestamp":1779232400375,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y\u2010HR2019\u20100367"],"award-info":[{"award-number":["Y\u2010HR2019\u20100367"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of combined chemotherapy and immunotherapy has previously been demonstrated in patients with biliary tract cancer. The aim of this study was to assess the efficacy and safety of camrelizumab in combination with gemcitabine and apatinib as a first\u2010 or second\u2010line treatment for advanced programmed death\u2010ligand 1 (PD\u2010L1)\u2010positive biliary tract cancer. This prospective, single\u2010arm, and exploratory clinical trial aimed at recruiting 20 PD\u2010L1\u2010positive patients (tumor proportion score\u2009\u22651% or combined positive score\u2009\u22651) who met the inclusion criteria. Camrelizumab (200\u2009mg) was administered in combination with gemcitabine (800\u2009mg\/m<jats:sup>2<\/jats:sup>) and apatinib (250\u2009mg). The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression\u2010free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Fourteen patients were enrolled between September 2, 2020, and December 15, 2022. At the data cutoff on August 16, 2023, the median follow\u2010up time was 11.4\u2009months (interquartile range, 4.5\u201315.4), with one patient still undergoing treatment. Among the enrolled patients, six achieved a partial response, and four had stable disease. The ORR was 42.9% (95% confidence interval [CI], 17.7\u201371.1), and the DCR was 71.4% (95% CI, 41.9\u201391.6). The median PFS was 5.4\u2009months (95% CI, 2.8\u2013not reached), and the median OS was 13.5\u2009months (95% CI, 5.7\u2013not reached). The most frequent grade 3 or 4 treatment\u2010related adverse event was neutropenia (<jats:italic>n<\/jats:italic>\u2009=\u20094, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD\u2010L1\u2010positive biliary tract cancer.<\/jats:p>","DOI":"10.1111\/cas.16376","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:25:03Z","timestamp":1730694303000},"page":"204-213","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Camrelizumab combined with gemcitabine and apatinib in treating advanced <scp>PD<\/scp>\u2010<scp>L1<\/scp>\u2010positive biliary tract cancers"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1650-8065","authenticated-orcid":false,"given":"Yitong","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"},{"name":"Department of Oncology The Fourth Affiliated Hospital of Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changxian","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Liyang People's Hospital  Liyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"You","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangcheng","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center The First Affiliated Hospital with Nanjing Medical University  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-951X","authenticated-orcid":false,"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital with Nanjing Medical University  Nanjing China"},{"name":"Gusu School Nanjing medical University  Suzhou China"},{"name":"Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University  Nanjing China"},{"name":"Department of Oncology Nanjing Pukou People's Hospital  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008352123009"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2276"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy282.009"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15641"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_2_11_13_1","first-page":"3","article-title":"Toripalimab in advanced biliary tract cancer","volume":"3","author":"Li W","year":"2022","journal-title":"Innovations"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01317-7"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02576-x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4100"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946861"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32548"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.493"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4520"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30086-X"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.438"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00679"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.4579"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15602"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.08.08"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13238"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.08.18"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.16376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:22:11Z","timestamp":1736396531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.16376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/cas.16376"],"URL":"https:\/\/doi.org\/10.1111\/cas.16376","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]},"assertion":[{"value":"2024-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}